Good Morning, Traders!…👋

The momentum behind the Trump trade appears to have stalled for now. Early on Friday, U.S. stock futures indicated potential losses, following a decline triggered the previous day by producer-price inflation data and remarks from Federal Reserve Chair Jerome Powell.

Futures for the Dow Jones Industrial Average fell 216 points, or 0.5%. S&P 500 futures were down 0.6%, while Nasdaq 100 futures dropped 0.8%.

In prepared comments for an event at the Dallas Regional Chamber on Thursday, Powell stated that the Fed did not need to be in a rush to lower rates. This came after the producer price index showed an expected 0.2% increase last month.

Meanwhile, the yield on the benchmark 10-year Treasury note was 4.444% early Thursday, remaining relatively unchanged from the previous day.

Happening Today

✓ 08:30 AM ET - Retail Sales (MoM) (Oct)

✓ 08:30 AM ET - Imoort & Export Price Index (MoM) (Oct)

✓ 09:15 AM ET – Industrial Production (MoM)(YoY) (Oct)

✓ 10:00 AM ET – Business Inventories (MoM) (Sep)

✓ 01:00 PM ET – Atlanta Fed GDPNow (Q4)

PREMARKET SNAPSHOT 📈

Market futures are down, with the S&P 500 declining 0.54%, the Dow falling 0.38%, and the NASDAQ dropping 0.79%.

SECTOR SNAPSHOT✨

Yesterday, the market faced widespread declines, with most sectors in the red. Consumer Discretionary and Health Care led the losses, both down by 1.54%. Industrials and Real Estate also saw significant declines, with Industrials dropping 1.69%. While Energy and Information Technology posted small gains of 0.14% and 0.05%, respectively, most sectors, including Consumer Staples, Financials, and Materials, faced losses. Utilities and Communication Services also ended the day lower, rounding out a day of overall market weakness.

PreMarket Unusual Volume Stocks

📈 Arena Group Holdings Inc (AREN) had an outstanding trading session with its stock price soaring 196.49% to close at $1.69. This surge was supported by an impressive volume of over 9.5 million shares, far surpassing its average volume of 146K. This significant gain reflects strong market interest and potential positive news or developments driving the stock upward.

📈 Greenidge Generation Holdings Inc (GREE) saw a substantial rise in its stock price, which increased by 65.99% to reach $4.10. The company traded over 10.4 million shares, well above its average volume of 306K, indicating heightened investor enthusiasm and renewed interest in this energy-focused company.

📈 Medicus Pharma Ltd (MDCX) experienced a decline of 5.66%, with its stock price falling to $2.50. The trading volume stood at 191K, compared to its average of 15K. This drop might indicate investor caution or profit-taking following recent activity in the pharmaceutical sector.

📈 Beneficient (BENF) posted an impressive 82.40% gain, closing at $2.28. The stock saw a significant trading volume of over 33.2 million shares, far exceeding its average of 3.8 million. This sharp increase highlights strong positive sentiment and heavy trading interest in the company.

📈 Innovation Beverage Group Ltd (IBG) recorded a 43.66% increase in its stock price, ending the day at $1.55. The volume reached over 2.7 million shares, surpassing its average of 701K. This rise points to growing interest and a positive market response to the company’s performance.

Premarket Picks

The Arena Group Holdings, Inc. (AREN) is trading at $1.4600 in pre-market, up 156.14% after reporting $4.0 million in net income for Q3 2024, marking its first-ever profitable quarter.

Beneficient (BENF) is trading at $2.48 in pre-market, up 98.40% after reporting Q2 fiscal 2025 results. Revenues increased to $8.6 million from a loss of $42.8 million in the same period last year, while operating expenses dropped significantly to $22.3 million, down from $339.0 million in Q2 fiscal 2024. The company also improved its permanent equity from a deficit of $148.3 million to $13.2 million.

Greenidge Generation Holdings Inc. (GREE) is trading at $3.90 in pre-market, up 57.89% after a New York State Supreme Court judge ruled that its Bitcoin mining facility at Seneca Lake can continue operations for now. This overturns a previous decision by the state DEC, which had denied the renewal of the company’s air permit.

Siyata Mobile Inc. (SYTA) is trading at $1.4700 in pre-market, up 14.84% after reporting Q3 revenue of $5.9 million, a 218% increase from $1.8 million in the same period last year. U.S. market revenue grew to $4.8 million, comprising 81% of total revenue. Gross margin improved to 29%, and the net loss narrowed to $0.6 million from $1.9 million last year.

Below is a complete list of hot stocks in pre-market today:

Top Upgrades:

1. Autolus Therapeutics (AUTL)

Analyst Firm: Redburn Atlantic
Upgrade: Neutral to Buy
Price Target: $13
Yesterday's Close: $3.15
Upside Potential: 312.7%

Redburn Atlantic has upgraded Autolus Therapeutics from Neutral to Buy, assigning a price target of $13. This implies a substantial upside potential of 312.7% from the current price of $3.15.

Over the past three months, five Wall Street analysts have offered 12-month price targets for AUTL, with projections ranging from a low of $8.00 to a high of $13.00, and an average target of $10.33. The average price target reflects a potential increase of 243.19% from the previous price of $3.01.

Autolus Therapeutics, known for its cutting-edge T-cell programming and innovative oncology treatments, stands out as a high-growth opportunity in the biotech sector. This upgrade by Redburn Atlantic underscores growing confidence in the company’s potential, making it a noteworthy option for investors seeking significant returns in the high-risk, high-reward biotechnology space.

2. AC Immune (ACIU)

• Analyst Firm: HC Wainwright & Co.

• Reiterates: Buy

• Price Target: $16

• Yesterday's Close: $3.47

• Upside Potential: 361.1%

HC Wainwright & Co. has reiterated its Buy rating on AC Immune, maintaining a price target of $16. This reflects an impressive upside potential of 361.1% from the current price of $3.47.

Over the last three months, three Wall Street analysts have provided 12-month price targets for AC Immune, with an average target of $11.00. These forecasts range from a low of $8.00 to a high of $16.00, suggesting a significant average upside of 209.86% from the last price of $3.55.

AC Immune, a company at the forefront of precision medicine and neurodegenerative disease research, continues to attract positive sentiment due to its robust therapeutic pipeline and innovative approaches. This reaffirmed Buy rating by HC Wainwright & Co. signals a strong conviction in the stock's future performance, positioning it as a potential high-reward investment in the biopharmaceutical sector.

3. Walt Disney (DIS)

• Analyst Firm: Deutsche Bank

• Maintains: Buy

• Price Target: Increased from $115 to $131

• Yesterday's Close: $108.53

• Upside Potential: 20.7%

Deutsche Bank has maintained its Buy rating on Walt Disney (NYSE: DIS) while raising its price target from $115 to $131. This reflects an upside potential of 20.7% from the current price of $108.53. In the past three months, 16 Wall Street analysts have issued 12-month price targets for Walt Disney, with an average target of $113.08. The forecasts range from a low of $91.00 to a high of $134.00, representing an average upside of 3.63% from the last price of $109.12.

Walt Disney continues to attract positive sentiment from analysts, underpinned by its broad entertainment ecosystem spanning media networks, theme parks, and direct-to-consumer streaming services. Deutsche Bank's increased price target indicates heightened confidence in Disney's recovery and growth potential, positioning it as an attractive investment for those looking for long-term value in the entertainment sector.

Happy investing,

Maeve Grace
Editor In Chief
Premium Stock Alerts

Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.

Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.